- Home
- PHI vs NUVL Comparison
PHI vs NUVL Comparison
Compare PHI & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHI
- NUVL
- Stock Information
- Founded
- PHI 1928
- NUVL 2017
- Country
- PHI Philippines
- NUVL United States
- Employees
- PHI N/A
- NUVL N/A
- Industry
- PHI Telecommunications Equipment
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- PHI Telecommunications
- NUVL Health Care
- Exchange
- PHI Nasdaq
- NUVL Nasdaq
- Market Cap
- PHI 4.8B
- NUVL 5.6B
- IPO Year
- PHI 1953
- NUVL 2021
- Fundamental
- Price
- PHI $21.70
- NUVL $75.54
- Analyst Decision
- PHI
- NUVL Strong Buy
- Analyst Count
- PHI 0
- NUVL 8
- Target Price
- PHI N/A
- NUVL $115.50
- AVG Volume (30 Days)
- PHI 61.5K
- NUVL 460.9K
- Earning Date
- PHI 08-12-2025
- NUVL 08-07-2025
- Dividend Yield
- PHI 7.81%
- NUVL N/A
- EPS Growth
- PHI 14.93
- NUVL N/A
- EPS
- PHI 2.54
- NUVL N/A
- Revenue
- PHI $3,804,539,911.00
- NUVL N/A
- Revenue This Year
- PHI $3.85
- NUVL N/A
- Revenue Next Year
- PHI $2.33
- NUVL N/A
- P/E Ratio
- PHI $8.37
- NUVL N/A
- Revenue Growth
- PHI 2.38
- NUVL N/A
- 52 Week Low
- PHI $20.29
- NUVL $55.54
- 52 Week High
- PHI $29.05
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- PHI 39.92
- NUVL 49.78
- Support Level
- PHI $21.68
- NUVL $76.42
- Resistance Level
- PHI $22.09
- NUVL $78.94
- Average True Range (ATR)
- PHI 0.37
- NUVL 2.70
- MACD
- PHI -0.07
- NUVL -0.23
- Stochastic Oscillator
- PHI 27.10
- NUVL 43.31
About PHI PLDT Inc. Sponsored ADR
PLDT Inc is the telecommunications carrier in the Philippines. The company's business activities include three business units: Wireless, Fixed Line and Others. The wireless segment consists of mobile telecommunications services provided by Smart and DMPI, and Fixed-line telecommunications services mainly provided by PLDT. It also provides fixed-line services through PLDT's subsidiaries.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.